 European Drug Agency To Weigh Risks/Benefits Of Tysabri -- Cites 23 Cases Of PMLMain Category: Multiple SclerosisAlso Included In: Regulatory Affairs / Drug Approvals Article Date: 27 Oct 2009 Today the EMEA, the European equivalent of the U.S. Food and Drug Administration, released a statement indicating that one of its advisory committees was launching a review of the risks and benefits of Tysabri® (natalizumab, Biogen Idec and Elan Pharmaceuticals) in light of 23 confirmed cases of PML that it says have occurred since the drug has been on the market. PML (progressive multifocal leukoencephalopathy) is a viral infection of the brain that usually leads to death or severe disability. (This number of cases is still within the anticipated frequency of 1 in 1,000 indicated in the drug's labeling.) Unlike the situation in the U.S, there is no unified risk management strategy in place across Europe for the administration of Tysabri. In the U.S., the drug is administered only to patients registered with the company's TOUCH program. The National MS Society will follow the European panel's deliberations on the safety of Tysabri and any new thoughts they might have on balancing the risks and benefits of this therapy for people with MS. Source National MS Society Original article posted on Medical News Today. Articles not to be reproduced without permission of Medical News Today Medical News Today publishes the latest health news and health videos for consumers and health professionals. It has a searchable archive of over 100,000 health news articles. < back to medical news
|
||||
|
Medical Abbreviations 
Medical Dictionary
ICD9 Codes
Medical Equipment
Hospitals Worldwide
Drugs Search
Pharma Companies
Medical Associations
Skin Conditions
PubMed Search
Other Searches
Free Tools & Content
News Newsletter
Directories
Product Directory
Transcription
Free Web Box
PDA Software
Membership
Web Developers
Tell a Friend
Funny Abbreviations
Useful Websites
Global TranslationsMedical and Clinical Translation
specialistinfo.com
Details of over 40,000 UK Specialists and over 42,000 GPs
Global RPH
medical software
Doctors Lounge
Ask a Doctor and Disease Information
Health News
from Medical News Today.
MRCP 1 Revision
123 Doc medical courses for junior doctors.
CoreyNahman
pharmaceutical news daily
Hospital Search
Worldwide hospital database, search by country or keyword.
Metric Conversions
The Converter Site - unit conversion tool.
news headlines 
email to a friend 
printer friendly 
sign up to newsletter 
PDA Medical Dictionary
only $15Take MediLexicon's abbreviations search with you where-ever you go with our PDA software. As an extra, this software is available with an extra medical dictionary...
>> Click here for more on the PDA Medical Dictionary <<
Add our searches to your Google homepage.
The 60 seconds challenge: Add these searches to your Google homepage within 60 seconds - simply click here and follow these instructions
Receive the latest medical news on your Google homepage.
The 60 seconds challenge: Receive the latest medical news on your Google homepage within 60 seconds - simply click here and follow these instructions
MediLexicon International Ltd, UK Office: +44 (0) 1625 415 347
MediLexicon International Ltd © 2009 All rights reserved.
